Transmission of Drug-Resistant HIV-1 Is Stabilizing in Europe
The SPREAD Programme investigated prospectively the time trend from September 2002 through December 2005 of transmitted drug resistance (TDR) among 2793 patients in 20 European countries and in Israel with newly diagnosed human immunodeficiency virus type 1 (HIV-1) infection. The overall prevalence...
Gespeichert in:
| Veröffentlicht in: | The Journal of infectious diseases 2009-11, Vol.200 (10), p.1503-1508 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1508 |
|---|---|
| container_issue | 10 |
| container_start_page | 1503 |
| container_title | The Journal of infectious diseases |
| container_volume | 200 |
| creator | Vercauteren, Jurgen Wensing, Annemarie M. J. van de Vijver, David A. M. C. Albert, Jan Balotta, Claudia Hamouda, Osamah Kücherer, Claudia Struck, Daniel Schmit, Jean-Claude Åsjö, Birgitta Bruckova, Marie Camacho, Ricardo J. Clotet, Bonaventura Coughlan, Suzie Grossman, Zehava Horban, Andrzej Korn, Klaus Kostrikis, Leondios Nielsen, Claus Paraskevis, Dimitrios Poljak, Mario Puchhammer-Stöckl, Elisabeth Riva, Chiara Ruiz, Lidia Salminen, Mika Schuurman, Rob Sonnerborg, Anders Stanekova, Danica Stanojevic, Maja Vandamme, Anne-Mieke Boucher, Charles A. B. |
| description | The SPREAD Programme investigated prospectively the time trend from September 2002 through December 2005 of transmitted drug resistance (TDR) among 2793 patients in 20 European countries and in Israel with newly diagnosed human immunodeficiency virus type 1 (HIV-1) infection. The overall prevalence of TDR was 8.4% (225 of 2687 patients; 95% confidence interval [CI], 7.4%–9.5%), the prevalence of nucleoside reverse-transcriptase inhibitor (NRTI) resistance was 4.7% (125 of 2687 patients; 95% CI, 3.9%–5.5%), the prevalence of nonucleoside reverse-transcriptase inhibitor (NNRTI) resistance was 2.3% (62 of 2687 patients; 95% CI, 1.8%–2.9%), and the prevalence of protease inhibitor (PI) resistance was 2.9% (79 of 2687 patients; 95% CI, 2.4%–3.6%). There was no time trend in the overall TDR or in NRTI resistance, but there was a statistically significant decrease in PI resistance (P=.04) and in NNRTI resistance after an initial increase (P=.02). We found that TDR appears to be stabilizing in Europe, consistent with recent reports of decreasing drug resistance and improved viral suppression in patients treated for HIV-1 infection |
| doi_str_mv | 10.1086/644505 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_555335</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>27794297</jstor_id><oup_id>10.1086/644505</oup_id><sourcerecordid>27794297</sourcerecordid><originalsourceid>FETCH-LOGICAL-c529t-bc2f7778fc9625666ebf268e9a41bbafedf40e3ce8e66dc1df516bb1950729c43</originalsourceid><addsrcrecordid>eNp10U1vFCEABmBibOxa9R9opgd7G-Wb4eDB1Opu3Ghi60d6IcBCQzs7TGEmrf310sxk9-QJAk9e4AWAVwi-Q7Dh7zmlDLInYIEYETXniDwFCwgxrlEj5SF4nvM1hJASLp6BQyQbwqhoFuDDRdJd3oacQ-yq6KtPabyqf7gc8qC7oVquftWoWuXqfNAmtOEhdFdV6KqzMcXevQAHXrfZvZzHI_Dz89nF6bJef_-yOv24ri3DcqiNxV4I0XgrOWacc2c85o2TmiJjtHcbT6Ej1jWO841FG88QNwZJBgWWlpIjUE-5-c71o1F9Clud_qqog5qXbsrMKcYYIaz4k8n3Kd6OLg-qvNC6ttWdi2NW5QqElzr20KaYc3J-F42geixWTcUW-GZOHM3WbfZsbrKAtzPQ2erWl1ptyDuHMcJIUlHc8eTi2P__sNeTuc5DTPsMISTFUuzrKJ_k7nf7Ot0oLohgavnnUn1dX_7G3yhW5-Qfpc6hhg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>66636000</pqid></control><display><type>article</type><title>Transmission of Drug-Resistant HIV-1 Is Stabilizing in Europe</title><source>Jstor Complete Legacy</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Alma/SFX Local Collection</source><source>SWEPUB Freely available online</source><creator>Vercauteren, Jurgen ; Wensing, Annemarie M. J. ; van de Vijver, David A. M. C. ; Albert, Jan ; Balotta, Claudia ; Hamouda, Osamah ; Kücherer, Claudia ; Struck, Daniel ; Schmit, Jean-Claude ; Åsjö, Birgitta ; Bruckova, Marie ; Camacho, Ricardo J. ; Clotet, Bonaventura ; Coughlan, Suzie ; Grossman, Zehava ; Horban, Andrzej ; Korn, Klaus ; Kostrikis, Leondios ; Nielsen, Claus ; Paraskevis, Dimitrios ; Poljak, Mario ; Puchhammer-Stöckl, Elisabeth ; Riva, Chiara ; Ruiz, Lidia ; Salminen, Mika ; Schuurman, Rob ; Sonnerborg, Anders ; Stanekova, Danica ; Stanojevic, Maja ; Vandamme, Anne-Mieke ; Boucher, Charles A. B.</creator><creatorcontrib>Vercauteren, Jurgen ; Wensing, Annemarie M. J. ; van de Vijver, David A. M. C. ; Albert, Jan ; Balotta, Claudia ; Hamouda, Osamah ; Kücherer, Claudia ; Struck, Daniel ; Schmit, Jean-Claude ; Åsjö, Birgitta ; Bruckova, Marie ; Camacho, Ricardo J. ; Clotet, Bonaventura ; Coughlan, Suzie ; Grossman, Zehava ; Horban, Andrzej ; Korn, Klaus ; Kostrikis, Leondios ; Nielsen, Claus ; Paraskevis, Dimitrios ; Poljak, Mario ; Puchhammer-Stöckl, Elisabeth ; Riva, Chiara ; Ruiz, Lidia ; Salminen, Mika ; Schuurman, Rob ; Sonnerborg, Anders ; Stanekova, Danica ; Stanojevic, Maja ; Vandamme, Anne-Mieke ; Boucher, Charles A. B.</creatorcontrib><description>The SPREAD Programme investigated prospectively the time trend from September 2002 through December 2005 of transmitted drug resistance (TDR) among 2793 patients in 20 European countries and in Israel with newly diagnosed human immunodeficiency virus type 1 (HIV-1) infection. The overall prevalence of TDR was 8.4% (225 of 2687 patients; 95% confidence interval [CI], 7.4%–9.5%), the prevalence of nucleoside reverse-transcriptase inhibitor (NRTI) resistance was 4.7% (125 of 2687 patients; 95% CI, 3.9%–5.5%), the prevalence of nonucleoside reverse-transcriptase inhibitor (NNRTI) resistance was 2.3% (62 of 2687 patients; 95% CI, 1.8%–2.9%), and the prevalence of protease inhibitor (PI) resistance was 2.9% (79 of 2687 patients; 95% CI, 2.4%–3.6%). There was no time trend in the overall TDR or in NRTI resistance, but there was a statistically significant decrease in PI resistance (P=.04) and in NNRTI resistance after an initial increase (P=.02). We found that TDR appears to be stabilizing in Europe, consistent with recent reports of decreasing drug resistance and improved viral suppression in patients treated for HIV-1 infection</description><identifier>ISSN: 0022-1899</identifier><identifier>EISSN: 1537-6613</identifier><identifier>DOI: 10.1086/644505</identifier><identifier>PMID: 19835478</identifier><identifier>CODEN: JIDIAQ</identifier><language>eng</language><publisher>Oxford: The University of Chicago Press</publisher><subject>Adult ; Antiretrovirals ; Biological and medical sciences ; Disease transmission ; Drug resistance ; Drug Resistance, Viral ; Europe - epidemiology ; Female ; Fundamental and applied biological sciences. Psychology ; Grants ; HIV ; HIV 1 ; HIV Infections - drug therapy ; HIV Infections - epidemiology ; HIV Infections - transmission ; HIV-1 - drug effects ; HIV-1 - genetics ; HIV/AIDS ; Humans ; Infections ; Infectious diseases ; Male ; Medical sciences ; Memory interference ; Microbiology ; Middle Aged ; Miscellaneous ; Prevalence ; Reverse Transcriptase Inhibitors - therapeutic use ; Statistical significance ; Virology ; Viruses</subject><ispartof>The Journal of infectious diseases, 2009-11, Vol.200 (10), p.1503-1508</ispartof><rights>2009 Infectious Diseases Society of America</rights><rights>2009 by the Infectious Diseases Society of America 2009</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c529t-bc2f7778fc9625666ebf268e9a41bbafedf40e3ce8e66dc1df516bb1950729c43</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/27794297$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/27794297$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>230,314,550,776,780,799,881,27901,27902,57992,58225</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22121947$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19835478$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:119523725$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Vercauteren, Jurgen</creatorcontrib><creatorcontrib>Wensing, Annemarie M. J.</creatorcontrib><creatorcontrib>van de Vijver, David A. M. C.</creatorcontrib><creatorcontrib>Albert, Jan</creatorcontrib><creatorcontrib>Balotta, Claudia</creatorcontrib><creatorcontrib>Hamouda, Osamah</creatorcontrib><creatorcontrib>Kücherer, Claudia</creatorcontrib><creatorcontrib>Struck, Daniel</creatorcontrib><creatorcontrib>Schmit, Jean-Claude</creatorcontrib><creatorcontrib>Åsjö, Birgitta</creatorcontrib><creatorcontrib>Bruckova, Marie</creatorcontrib><creatorcontrib>Camacho, Ricardo J.</creatorcontrib><creatorcontrib>Clotet, Bonaventura</creatorcontrib><creatorcontrib>Coughlan, Suzie</creatorcontrib><creatorcontrib>Grossman, Zehava</creatorcontrib><creatorcontrib>Horban, Andrzej</creatorcontrib><creatorcontrib>Korn, Klaus</creatorcontrib><creatorcontrib>Kostrikis, Leondios</creatorcontrib><creatorcontrib>Nielsen, Claus</creatorcontrib><creatorcontrib>Paraskevis, Dimitrios</creatorcontrib><creatorcontrib>Poljak, Mario</creatorcontrib><creatorcontrib>Puchhammer-Stöckl, Elisabeth</creatorcontrib><creatorcontrib>Riva, Chiara</creatorcontrib><creatorcontrib>Ruiz, Lidia</creatorcontrib><creatorcontrib>Salminen, Mika</creatorcontrib><creatorcontrib>Schuurman, Rob</creatorcontrib><creatorcontrib>Sonnerborg, Anders</creatorcontrib><creatorcontrib>Stanekova, Danica</creatorcontrib><creatorcontrib>Stanojevic, Maja</creatorcontrib><creatorcontrib>Vandamme, Anne-Mieke</creatorcontrib><creatorcontrib>Boucher, Charles A. B.</creatorcontrib><title>Transmission of Drug-Resistant HIV-1 Is Stabilizing in Europe</title><title>The Journal of infectious diseases</title><addtitle>The Journal of Infectious Diseases</addtitle><addtitle>The Journal of Infectious Diseases</addtitle><description>The SPREAD Programme investigated prospectively the time trend from September 2002 through December 2005 of transmitted drug resistance (TDR) among 2793 patients in 20 European countries and in Israel with newly diagnosed human immunodeficiency virus type 1 (HIV-1) infection. The overall prevalence of TDR was 8.4% (225 of 2687 patients; 95% confidence interval [CI], 7.4%–9.5%), the prevalence of nucleoside reverse-transcriptase inhibitor (NRTI) resistance was 4.7% (125 of 2687 patients; 95% CI, 3.9%–5.5%), the prevalence of nonucleoside reverse-transcriptase inhibitor (NNRTI) resistance was 2.3% (62 of 2687 patients; 95% CI, 1.8%–2.9%), and the prevalence of protease inhibitor (PI) resistance was 2.9% (79 of 2687 patients; 95% CI, 2.4%–3.6%). There was no time trend in the overall TDR or in NRTI resistance, but there was a statistically significant decrease in PI resistance (P=.04) and in NNRTI resistance after an initial increase (P=.02). We found that TDR appears to be stabilizing in Europe, consistent with recent reports of decreasing drug resistance and improved viral suppression in patients treated for HIV-1 infection</description><subject>Adult</subject><subject>Antiretrovirals</subject><subject>Biological and medical sciences</subject><subject>Disease transmission</subject><subject>Drug resistance</subject><subject>Drug Resistance, Viral</subject><subject>Europe - epidemiology</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Grants</subject><subject>HIV</subject><subject>HIV 1</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - epidemiology</subject><subject>HIV Infections - transmission</subject><subject>HIV-1 - drug effects</subject><subject>HIV-1 - genetics</subject><subject>HIV/AIDS</subject><subject>Humans</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Memory interference</subject><subject>Microbiology</subject><subject>Middle Aged</subject><subject>Miscellaneous</subject><subject>Prevalence</subject><subject>Reverse Transcriptase Inhibitors - therapeutic use</subject><subject>Statistical significance</subject><subject>Virology</subject><subject>Viruses</subject><issn>0022-1899</issn><issn>1537-6613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>D8T</sourceid><recordid>eNp10U1vFCEABmBibOxa9R9opgd7G-Wb4eDB1Opu3Ghi60d6IcBCQzs7TGEmrf310sxk9-QJAk9e4AWAVwi-Q7Dh7zmlDLInYIEYETXniDwFCwgxrlEj5SF4nvM1hJASLp6BQyQbwqhoFuDDRdJd3oacQ-yq6KtPabyqf7gc8qC7oVquftWoWuXqfNAmtOEhdFdV6KqzMcXevQAHXrfZvZzHI_Dz89nF6bJef_-yOv24ri3DcqiNxV4I0XgrOWacc2c85o2TmiJjtHcbT6Ej1jWO841FG88QNwZJBgWWlpIjUE-5-c71o1F9Clud_qqog5qXbsrMKcYYIaz4k8n3Kd6OLg-qvNC6ttWdi2NW5QqElzr20KaYc3J-F42geixWTcUW-GZOHM3WbfZsbrKAtzPQ2erWl1ptyDuHMcJIUlHc8eTi2P__sNeTuc5DTPsMISTFUuzrKJ_k7nf7Ot0oLohgavnnUn1dX_7G3yhW5-Qfpc6hhg</recordid><startdate>20091115</startdate><enddate>20091115</enddate><creator>Vercauteren, Jurgen</creator><creator>Wensing, Annemarie M. J.</creator><creator>van de Vijver, David A. M. C.</creator><creator>Albert, Jan</creator><creator>Balotta, Claudia</creator><creator>Hamouda, Osamah</creator><creator>Kücherer, Claudia</creator><creator>Struck, Daniel</creator><creator>Schmit, Jean-Claude</creator><creator>Åsjö, Birgitta</creator><creator>Bruckova, Marie</creator><creator>Camacho, Ricardo J.</creator><creator>Clotet, Bonaventura</creator><creator>Coughlan, Suzie</creator><creator>Grossman, Zehava</creator><creator>Horban, Andrzej</creator><creator>Korn, Klaus</creator><creator>Kostrikis, Leondios</creator><creator>Nielsen, Claus</creator><creator>Paraskevis, Dimitrios</creator><creator>Poljak, Mario</creator><creator>Puchhammer-Stöckl, Elisabeth</creator><creator>Riva, Chiara</creator><creator>Ruiz, Lidia</creator><creator>Salminen, Mika</creator><creator>Schuurman, Rob</creator><creator>Sonnerborg, Anders</creator><creator>Stanekova, Danica</creator><creator>Stanojevic, Maja</creator><creator>Vandamme, Anne-Mieke</creator><creator>Boucher, Charles A. B.</creator><general>The University of Chicago Press</general><general>University of Chicago Press</general><general>Oxford University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>ZZAVC</scope></search><sort><creationdate>20091115</creationdate><title>Transmission of Drug-Resistant HIV-1 Is Stabilizing in Europe</title><author>Vercauteren, Jurgen ; Wensing, Annemarie M. J. ; van de Vijver, David A. M. C. ; Albert, Jan ; Balotta, Claudia ; Hamouda, Osamah ; Kücherer, Claudia ; Struck, Daniel ; Schmit, Jean-Claude ; Åsjö, Birgitta ; Bruckova, Marie ; Camacho, Ricardo J. ; Clotet, Bonaventura ; Coughlan, Suzie ; Grossman, Zehava ; Horban, Andrzej ; Korn, Klaus ; Kostrikis, Leondios ; Nielsen, Claus ; Paraskevis, Dimitrios ; Poljak, Mario ; Puchhammer-Stöckl, Elisabeth ; Riva, Chiara ; Ruiz, Lidia ; Salminen, Mika ; Schuurman, Rob ; Sonnerborg, Anders ; Stanekova, Danica ; Stanojevic, Maja ; Vandamme, Anne-Mieke ; Boucher, Charles A. B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c529t-bc2f7778fc9625666ebf268e9a41bbafedf40e3ce8e66dc1df516bb1950729c43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adult</topic><topic>Antiretrovirals</topic><topic>Biological and medical sciences</topic><topic>Disease transmission</topic><topic>Drug resistance</topic><topic>Drug Resistance, Viral</topic><topic>Europe - epidemiology</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Grants</topic><topic>HIV</topic><topic>HIV 1</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - epidemiology</topic><topic>HIV Infections - transmission</topic><topic>HIV-1 - drug effects</topic><topic>HIV-1 - genetics</topic><topic>HIV/AIDS</topic><topic>Humans</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Memory interference</topic><topic>Microbiology</topic><topic>Middle Aged</topic><topic>Miscellaneous</topic><topic>Prevalence</topic><topic>Reverse Transcriptase Inhibitors - therapeutic use</topic><topic>Statistical significance</topic><topic>Virology</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vercauteren, Jurgen</creatorcontrib><creatorcontrib>Wensing, Annemarie M. J.</creatorcontrib><creatorcontrib>van de Vijver, David A. M. C.</creatorcontrib><creatorcontrib>Albert, Jan</creatorcontrib><creatorcontrib>Balotta, Claudia</creatorcontrib><creatorcontrib>Hamouda, Osamah</creatorcontrib><creatorcontrib>Kücherer, Claudia</creatorcontrib><creatorcontrib>Struck, Daniel</creatorcontrib><creatorcontrib>Schmit, Jean-Claude</creatorcontrib><creatorcontrib>Åsjö, Birgitta</creatorcontrib><creatorcontrib>Bruckova, Marie</creatorcontrib><creatorcontrib>Camacho, Ricardo J.</creatorcontrib><creatorcontrib>Clotet, Bonaventura</creatorcontrib><creatorcontrib>Coughlan, Suzie</creatorcontrib><creatorcontrib>Grossman, Zehava</creatorcontrib><creatorcontrib>Horban, Andrzej</creatorcontrib><creatorcontrib>Korn, Klaus</creatorcontrib><creatorcontrib>Kostrikis, Leondios</creatorcontrib><creatorcontrib>Nielsen, Claus</creatorcontrib><creatorcontrib>Paraskevis, Dimitrios</creatorcontrib><creatorcontrib>Poljak, Mario</creatorcontrib><creatorcontrib>Puchhammer-Stöckl, Elisabeth</creatorcontrib><creatorcontrib>Riva, Chiara</creatorcontrib><creatorcontrib>Ruiz, Lidia</creatorcontrib><creatorcontrib>Salminen, Mika</creatorcontrib><creatorcontrib>Schuurman, Rob</creatorcontrib><creatorcontrib>Sonnerborg, Anders</creatorcontrib><creatorcontrib>Stanekova, Danica</creatorcontrib><creatorcontrib>Stanojevic, Maja</creatorcontrib><creatorcontrib>Vandamme, Anne-Mieke</creatorcontrib><creatorcontrib>Boucher, Charles A. B.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SwePub Articles full text</collection><jtitle>The Journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vercauteren, Jurgen</au><au>Wensing, Annemarie M. J.</au><au>van de Vijver, David A. M. C.</au><au>Albert, Jan</au><au>Balotta, Claudia</au><au>Hamouda, Osamah</au><au>Kücherer, Claudia</au><au>Struck, Daniel</au><au>Schmit, Jean-Claude</au><au>Åsjö, Birgitta</au><au>Bruckova, Marie</au><au>Camacho, Ricardo J.</au><au>Clotet, Bonaventura</au><au>Coughlan, Suzie</au><au>Grossman, Zehava</au><au>Horban, Andrzej</au><au>Korn, Klaus</au><au>Kostrikis, Leondios</au><au>Nielsen, Claus</au><au>Paraskevis, Dimitrios</au><au>Poljak, Mario</au><au>Puchhammer-Stöckl, Elisabeth</au><au>Riva, Chiara</au><au>Ruiz, Lidia</au><au>Salminen, Mika</au><au>Schuurman, Rob</au><au>Sonnerborg, Anders</au><au>Stanekova, Danica</au><au>Stanojevic, Maja</au><au>Vandamme, Anne-Mieke</au><au>Boucher, Charles A. B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Transmission of Drug-Resistant HIV-1 Is Stabilizing in Europe</atitle><jtitle>The Journal of infectious diseases</jtitle><stitle>The Journal of Infectious Diseases</stitle><addtitle>The Journal of Infectious Diseases</addtitle><date>2009-11-15</date><risdate>2009</risdate><volume>200</volume><issue>10</issue><spage>1503</spage><epage>1508</epage><pages>1503-1508</pages><issn>0022-1899</issn><eissn>1537-6613</eissn><coden>JIDIAQ</coden><abstract>The SPREAD Programme investigated prospectively the time trend from September 2002 through December 2005 of transmitted drug resistance (TDR) among 2793 patients in 20 European countries and in Israel with newly diagnosed human immunodeficiency virus type 1 (HIV-1) infection. The overall prevalence of TDR was 8.4% (225 of 2687 patients; 95% confidence interval [CI], 7.4%–9.5%), the prevalence of nucleoside reverse-transcriptase inhibitor (NRTI) resistance was 4.7% (125 of 2687 patients; 95% CI, 3.9%–5.5%), the prevalence of nonucleoside reverse-transcriptase inhibitor (NNRTI) resistance was 2.3% (62 of 2687 patients; 95% CI, 1.8%–2.9%), and the prevalence of protease inhibitor (PI) resistance was 2.9% (79 of 2687 patients; 95% CI, 2.4%–3.6%). There was no time trend in the overall TDR or in NRTI resistance, but there was a statistically significant decrease in PI resistance (P=.04) and in NNRTI resistance after an initial increase (P=.02). We found that TDR appears to be stabilizing in Europe, consistent with recent reports of decreasing drug resistance and improved viral suppression in patients treated for HIV-1 infection</abstract><cop>Oxford</cop><pub>The University of Chicago Press</pub><pmid>19835478</pmid><doi>10.1086/644505</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-1899 |
| ispartof | The Journal of infectious diseases, 2009-11, Vol.200 (10), p.1503-1508 |
| issn | 0022-1899 1537-6613 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_555335 |
| source | Jstor Complete Legacy; Oxford University Press Journals All Titles (1996-Current); MEDLINE; Alma/SFX Local Collection; SWEPUB Freely available online |
| subjects | Adult Antiretrovirals Biological and medical sciences Disease transmission Drug resistance Drug Resistance, Viral Europe - epidemiology Female Fundamental and applied biological sciences. Psychology Grants HIV HIV 1 HIV Infections - drug therapy HIV Infections - epidemiology HIV Infections - transmission HIV-1 - drug effects HIV-1 - genetics HIV/AIDS Humans Infections Infectious diseases Male Medical sciences Memory interference Microbiology Middle Aged Miscellaneous Prevalence Reverse Transcriptase Inhibitors - therapeutic use Statistical significance Virology Viruses |
| title | Transmission of Drug-Resistant HIV-1 Is Stabilizing in Europe |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T16%3A32%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Transmission%20of%20Drug-Resistant%20HIV-1%20Is%20Stabilizing%20in%20Europe&rft.jtitle=The%20Journal%20of%20infectious%20diseases&rft.au=Vercauteren,%20Jurgen&rft.date=2009-11-15&rft.volume=200&rft.issue=10&rft.spage=1503&rft.epage=1508&rft.pages=1503-1508&rft.issn=0022-1899&rft.eissn=1537-6613&rft.coden=JIDIAQ&rft_id=info:doi/10.1086/644505&rft_dat=%3Cjstor_swepu%3E27794297%3C/jstor_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=66636000&rft_id=info:pmid/19835478&rft_jstor_id=27794297&rft_oup_id=10.1086/644505&rfr_iscdi=true |